References
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
- Regionala Cancercentrum. Endometrie-/corpuscancer – Nationellt vårdprogram. 2022. https://cancercentrum.se/globalassets/cancerdiagnoser/gynekologi/livmoderkroppscancer/vardprogram/nationellt-vardprogram-endometriecancer.pdf.
- Heffernan K, Nikitas FS, Shukla U, et al. Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis. Gynecol Oncol. 2022;166(2):317–325. doi: 10.1016/j.ygyno.2022.06.011.
- Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi33–vi38. doi: 10.1093/annonc/mdt353.
- European Medicines Agency. Keytruda (pembrolizumab). 2022. https://www.ema.europa.eu/en/documents/overview/keytruda-epar-medicine-overview_en.pdf.
- Eisai GmbH. LEVIMA summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_en.pdf.
- Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi: 10.1056/NEJMoa2108330.
- Bateman AC. DNA mismatch repair proteins: scientific update and practical guide. J Clin Pathol. 2021;74(4):264–268. doi: 10.1136/jclinpath-2020-207281.
- Tandvårds- och läkemedelsförmånsverket (TLV). Change in the dental and pharmaceutical benefits agency general advice (TLVAR 2003:2) on financial evaluations. 2017. https://www.tlv.se/download/18.467926b615d084471ac3230c/1510316374332/TLVAR_2017_1.pdf
- National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. 2023. https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741.
- Tandvårds- och läkemedelsförmånsverket (TLV). Basis for decisions in the regions, Opdivo (nivolumab) plus Yervoy (ipilimumab) combination therapy. 2019. https://www.tlv.se/download/18.2e325bfb16afd0e62b51fb11/1559116883979/bes190515_opdivo_yervoy.pdf.
- Woods B, Sideris E, Palmer S, et al. NICE DSU technical support document 19. Partitioned survival analysis for decision modelling in health care: a critical review. 2017. https://pure.york.ac.uk/portal/en/publications/nice-dsu-technical-support-document-19-partitioned-survival-analy.
- Makker V, Colombo N, Herraez A, et al. 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): study 309/KEYNOTE-775. Ann Oncol. 2022;33(suppl_7):S785–786. doi: 10.1016/j.annonc.2022.07.653
- Tandvårds- och läkemedelsförmånsverket (TLV). TLV database. 2021. https://www.tlv.se/beslut/sok-i-databasen.html.
- Southern Healthcare Region. Regional prices and compensation for the Southern Healthcare Region. 2021. https://sodrasjukvardsregionen.se/download/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2020/?wpdmdl=14479&masterkey=5e3037d356c07.
- Latimer NI. NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. https://www.sheffield.ac.uk/nice-dsu/tsds/full-list.
- Rutherford MJ, Lambert PC, Sweeting MJ, et al. NICE DSU technical support document 21: flexible methods for survival analysis. 2020. https://www.sheffield.ac.uk/nice-dsu/tsds/full-list.
- Makker V, Aghajanian C, Cohn AL, et al. A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (study 111/KEYNOTE-146): long-term efficacy and safety update. J Clin Oncol. 2023;41(5):974–979. doi: 10.1200/JCO.22.01021.
- Latimer NR, Abrams KR. National Institute for Health and Care Excellence (NICE) Decision Support Unit. Technical support document 16: adjusting survival time estimates in the presence of treatment switching. 2014. https://www.ncbi.nlm.nih.gov/books/NBK310374/pdf/Bookshelf_NBK310374.pdf
- Burström K, Teni FS, Gerdtham U-G, et al. Experience-based Swedish TTO and VAS value sets for EQ-5D-5L health states. Pharmacoeconomics. 2020;38(8):839–856. doi: 10.1007/s40273-020-00905-7.
- Apoteket. All products. 2021. https://www.apoteket.se/kategori/.
- National Institute for Health and Care Excellence (NICE). Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [TA620]. 2020. https://www.nice.org.uk/guidance/ta620.
- Statistics Sweden. CPI, fixed index numbers (1980 = 100). 2021. https://www.scb.se/en/finding-statistics/statistics-by-subject-area/prices-and-consumption/consumer-price-index/consumer-price-index-cpi/pong/tables-and-graphs/consumer-price-index-cpi/cpi-fixed-index-numbers-1980100/
- Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. J Clin Oncol. 2023;41(16):2904–2910. doi: 10.1200/JCO.22.02152.
- van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89–91. doi: 10.1136/ard.2009.117150.
- Priyadarshini M, Prabhu VS, Snedecor SJ, et al. Economic value of lost productivity attributable to human papillomavirus cancer mortality in the United States. Front Public Health. 2020;8:624092. doi: 10.3389/fpubh.2020.624092.
- McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study. Gynecol Oncol. 2007;106(1):16–22. doi: 10.1016/j.ygyno.2007.04.032.
- Thurgar E, Gouldson M, Matthijsse S, et al. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. J Med Econ. 2021;24(1):675–688. doi: 10.1080/13696998.2021.1917140.
- Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–2992. doi: 10.1200/JCO.19.02627.